Daniel Junius from Waltham, MA

Wikipedia

Junius Daniel

view source

Junius Daniel (June 27, 1828 May 13, 1864) was a planter and career military officer, serving in the United States Army, then in the Confederate States ...

Resumes

Daniel Junius

view source

Location:

Greater Boston Area

Industry:

Biotechnology

Daniel Junius

view source

Location:

Greater Boston Area

Industry:

Business Supplies and Equipment

Name / Title

Company / Classification

Phones & Addresses

Daniel M Junius
President

IMMUNOGEN SECURITIES CORP

830 Winter St, Waltham, MA 02451

Daniel M. Junius
President, Chief Executive Officer

ImmunoGen, Inc.
Biotechnology · Medical Research & Development of Antibody-Based Anticancer Therapeutics/Pharmaceutical Preparations · Pharmaceutical Preparations

830 Winter St, Waltham, MA 02451
7818950600, 6179952500

Daniel M. Junius
Soc signatory

HURRICANE, LLC

830 Winter St, Waltham, MA 02451

Daniel M. Junius
Treasurer

NASHUA MEDIA, INC

44 Franklin St, Nashua, NH 03060
12 Crestwood Ct, Amherst, NH 03031

Daniel M. Junius

NASHUA CORPORATION

417 Spg St, Little Rock, AR 72201
44 Franklin St, Nashua, NH

Daniel M. Junius
Treasurer, Treasurer, Director, Director

PREMIUMWEAR, INC

Service, Groton, MA 01471
C/O Jim Bury 5500 Feltl Rd, Hopkins, MN 55343
500 Main St, Groton, MA 01471

News

Special News: ImmunoGen, Inc. (NASDAQ:IMGN), Celgene Corporation ...

view source

ImmunoGen, Inc. (NASDAQ:IMGN)s shares plunged 47.46% to $5.80. The company announced that Daniel Junius, President and CEO, will present at the upcoming 33rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 9:00 am PT on January 13, 2015.
Date: Dec 19, 2014
Category: Health
Source: Google

FDA OK's breast cancer drug created in part by ImmunoGen

view source

This is the first of what I expect to be many (drug) approvals for this company, Daniel Junius, chief executive of ImmunoGen, said Friday. Theres an expectation that this will be a very significant drug over time. Its a little bit of icing on the cake in terms of validating our technology.
Date: Feb 23, 2013
Category: Health
Source: Google

Roche's T-DM1 generates a fresh blast of positive PhII data

view source

"It is noteworthy that single-agent therapy with trastuzumab emtansine demonstrated both efficacy and tolerability advantages over Herceptin given with separate chemotherapy," commented ImmunoGen CEO Daniel Junius. "We expect the body of impressive clinical results to grow substantially as the numbe
Date: Sep 26, 2011
Category: Health
Source: Google

ImmunoGen shares rise on positive study results

view source

"This top-line information about T-DM1's performance in the first-line setting is very encouraging and adds to the favorable efficacy and safety data reported across a number of T-DM1 studies," said ImmunoGen President and CEO Daniel Junius, in a statement.
Date: Apr 08, 2011
Category: Health
Source: Google